Early tests suggest gene-edited beagles may produce no detectable major dog allergen, Can f 1, potentially advancing approaches aimed at reducing dog allergy symptoms. The work described initial findings for people who react primarily to dog saliva proteins, a pathway that underlies existing immunotherapy and allergen-avoidance strategies. While the report centers on preclinical or early-stage detection rather than clinical outcomes, it signals that genetic targeting of the allergen source could move beyond topical or exposure-management approaches. For allergen immunotherapy programs, a reliable source-reduction strategy could change product positioning. The next proof point will be whether allergen-free production translates into measurable symptom reduction for sensitized individuals under real-world exposure conditions.